JAZZ Relative Valuation
JAZZ's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAZZ is overvalued; if below, it's undervalued.
Historical Valuation
Jazz Pharmaceuticals PLC (JAZZ) is now in the Fair zone, suggesting that its current forward PE ratio of 14.94 is considered Fairly compared with the five-year average of 8.30. The fair price of Jazz Pharmaceuticals PLC (JAZZ) is between 113.65 to 143.54 according to relative valuation methord.
Relative Value
Fair Zone
113.65-143.54
Current Price：116.10
Fair
14.66
PE
1Y
3Y
5Y
Trailing
Forward
9.36
EV/EBITDA
Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBITDA of 9.36. The 5-year average EV/EBITDA is 7.55. The thresholds are as follows: Strongly Undervalued below 4.82, Undervalued between 4.82 and 6.18, Fairly Valued between 8.91 and 6.18, Overvalued between 8.91 and 10.28, and Strongly Overvalued above 10.28. The current Forward EV/EBITDA of 9.36 falls within the Overvalued range.
10.09
EV/EBIT
Jazz Pharmaceuticals PLC. (JAZZ) has a current EV/EBIT of 10.09. The 5-year average EV/EBIT is 7.98. The thresholds are as follows: Strongly Undervalued below 4.85, Undervalued between 4.85 and 6.42, Fairly Valued between 9.55 and 6.42, Overvalued between 9.55 and 11.12, and Strongly Overvalued above 11.12. The current Forward EV/EBIT of 10.09 falls within the Overvalued range.
1.63
PS
Jazz Pharmaceuticals PLC. (JAZZ) has a current PS of 1.63. The 5-year average PS is 2.30. The thresholds are as follows: Strongly Undervalued below 1.24, Undervalued between 1.24 and 1.77, Fairly Valued between 2.83 and 1.77, Overvalued between 2.83 and 3.36, and Strongly Overvalued above 3.36. The current Forward PS of 1.63 falls within the Undervalued range.
14.34
P/OCF
Jazz Pharmaceuticals PLC. (JAZZ) has a current P/OCF of 14.34. The 5-year average P/OCF is 6.95. The thresholds are as follows: Strongly Undervalued below 3.15, Undervalued between 3.15 and 5.05, Fairly Valued between 8.84 and 5.05, Overvalued between 8.84 and 10.74, and Strongly Overvalued above 10.74. The current Forward P/OCF of 14.34 falls within the Strongly Overvalued range.
7.41
P/FCF
Jazz Pharmaceuticals PLC. (JAZZ) has a current P/FCF of 7.41. The 5-year average P/FCF is 6.87. The thresholds are as follows: Strongly Undervalued below 3.74, Undervalued between 3.74 and 5.31, Fairly Valued between 8.44 and 5.31, Overvalued between 8.44 and 10.00, and Strongly Overvalued above 10.00. The current Forward P/FCF of 7.41 falls within the Historic Trend Line -Fairly Valued range.
Jazz Pharmaceuticals PLC (JAZZ) has a current Price-to-Book (P/B) ratio of 1.71. Compared to its 3-year average P/B ratio of 2.26 , the current P/B ratio is approximately -24.58% higher. Relative to its 5-year average P/B ratio of 2.33, the current P/B ratio is about -26.70% higher. Jazz Pharmaceuticals PLC (JAZZ) has a Forward Free Cash Flow (FCF) yield of approximately 21.65%. Compared to its 3-year average FCF yield of 15.32%, the current FCF yield is approximately 41.32% lower. Relative to its 5-year average FCF yield of 12.77% , the current FCF yield is about 69.58% lower.
1.67
P/B
Median3y
2.26
Median5y
2.33
21.54
FCF Yield
Median3y
15.32
Median5y
12.77
Competitors Valuation Multiple
The average P/S ratio for JAZZ's competitors is 7.06, providing a benchmark for relative valuation. Jazz Pharmaceuticals PLC Corp (JAZZ) exhibits a P/S ratio of 1.63, which is -76.93% above the industry average. Given its robust revenue growth of -0.46%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of JAZZ increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of JAZZ in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Jazz Pharmaceuticals PLC (JAZZ) currently overvalued or undervalued?
What is Jazz Pharmaceuticals PLC (JAZZ) fair value?
How does JAZZ's valuation metrics compare to the industry average?
What is the current P/B ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Aug 06 2025?
What is the current FCF Yield for Jazz Pharmaceuticals PLC (JAZZ) as of Aug 06 2025?
What is the current Forward P/E ratio for Jazz Pharmaceuticals PLC (JAZZ) as of Aug 06 2025?